bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Here’s What Happened

bioMerieux (OTCMKTS:BMXMF)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $86.88, but opened at $83.27. bioMerieux shares last traded at $83.27, with a volume of 302 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. UBS Group cut bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Morgan Stanley reaffirmed an “underweight” rating on shares of bioMerieux in a report on Friday, September 11th. Zacks Research lowered bioMerieux from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Finally, Piper Sandler started coverage on bioMerieux in a report on Thursday, June 11th. They issued a “neutral” rating for the company. Four research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Reduce”.

bioMerieux Price Performance

The business’s 50-day moving average is $82.58 and its two-hundred day moving average is $89.97. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39.

About bioMerieux

bioMérieux (OTCMKTS:BMXMF) is a France-based company specializing in in vitro diagnostics. It develops, manufactures and markets diagnostic systems used to detect infectious diseases, support antimicrobial treatment decisions and improve patient care in clinical settings.

The company’s product portfolio includes molecular biology tests, microbiology systems, immunoassays and syndromic testing solutions. Its clinical diagnostic products are used by hospitals, laboratories and other healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetic industries through solutions for detecting microorganisms and monitoring contamination.

Established in 1963, bioMérieux traces its roots to the Mérieux family’s longstanding involvement in medical research and diagnostics in France.